Biogen revealed detailed results from its Alzheimer’s trial to a jam-packed room of eager conference attendees this week—and while some described it as a major advance in the field, others were less convinced.
Samantha Budd Haeberlein, Biogen’s vice president of clinical development, took the stage Thursday morning in San Diego at Clinical Trials on Alzheimer’s Disease (CTAD) to reveal data the company says supports its plan to ask the FDA to review its experimental Alzheimer’s drug, aducanamab. If approved, the drug would be the first marketed to change the course of the neurodegenerative disease.
The potentially multi-billion dollar question that underpinned… Read more »
UNDERWRITERS AND PARTNERS
